# HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada

> **NCT06386263** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 22 (actual)

## Conditions studied

- Unresectable Breast Cancer
- Metastatic Breast Cancer
- HER2-low Expressing Breast Cancer
- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Trastuzumab deruxtecan

## Key facts

- **NCT ID:** NCT06386263
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-22
- **Primary completion:** 2025-07-07
- **Final completion:** 2025-07-07
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-10-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06386263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06386263, "HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06386263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*